D. E. Shaw & Co., Inc. - NGM BIOPHARMACEUTICALS INC ownership

NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of NGM BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$345,045
-62.5%
322,472
-9.1%
0.00%
-100.0%
Q2 2023$919,165
-18.7%
354,890
+28.1%
0.00%0.0%
Q1 2023$1,130,462
+83.1%
277,074
+125.3%
0.00%0.0%
Q4 2022$617,239
-66.1%
122,956
-11.7%
0.00%
-50.0%
Q3 2022$1,821,000
-11.7%
139,257
-13.4%
0.00%0.0%
Q2 2022$2,062,000
+113.2%
160,865
+153.7%
0.00%
+100.0%
Q1 2022$967,000
-9.0%
63,397
+5.6%
0.00%0.0%
Q4 2021$1,063,000
+12.1%
60,031
+33.2%
0.00%0.0%
Q3 2021$948,000
+6.5%
45,078
-0.1%
0.00%0.0%
Q2 2021$890,000
+200.7%
45,138
+343.1%
0.00%
Q1 2021$296,00010,1880.00%
Other shareholders
NGM BIOPHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Greenspring Associates, LLC 1,573,357$47,665,00061.89%
RHO CAPITAL PARTNERS INC 3,766,666$114,111,00060.06%
Column Group LLC 15,396,116$466,502,00042.31%
Ponoi II Management, LLC 1,298,908$39,357,00028.68%
Ponoi Management, LLC 1,298,908$39,357,00022.52%
Euclidean Capital LLC 2,083,602$63,133,00013.36%
Aquilo Capital Management, LLC 1,005,534$30,463,0006.33%
Octagon Capital Advisors LP 75,227$2,279,0000.79%
Jasper Ridge Partners, L.P. 308,750$9,354,0000.41%
Point72 Asset Management, L.P. 1,761,157$53,354,0000.26%
View complete list of NGM BIOPHARMACEUTICALS INC shareholders